NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

At around page 42, CRL gives their Cell & Gene Therapy Scientific Overview, and that's where they discuss more of the Cognate related topics.

Then deep into the slide deck, on page 80, they indicate that Cognate CURRENTLY has 22 suites for US/EU GMP cell therapy. Remember that Sawston currently has two, and can handle about 45 to 50 a month w those two suites. Of course, the Flaskworks system, when optimized and approved for manufacturing use, will dramatically change the UK capacity.

In the meantime, though, I think it's useful to note the current Cognate capacity... and that they intend to add 9 more suites by the end of 2022.